Cargando…

Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis

In a pooled population analysis, we investigated the pharmacokinetics of i.v. anidulafungin in four studies across a full range of adult and pediatric ages in patients with confirmed, suspected, or at high risk of invasive candidiasis (IC). Relationships between anidulafungin exposure and key effica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Rujia, McFadyen, Lynn, Raber, Susan, Swanson, Robert, Tawadrous, Margaret, Leister‐Tebbe, Heidi, Cohen‐Wolkowiez, Michael, Benjamin, Daniel K., Liu, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485140/ https://www.ncbi.nlm.nih.gov/pubmed/32189334 http://dx.doi.org/10.1002/cpt.1831

Ejemplares similares

Safety and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children
por: Roilides, Emmanuel, et al.
Publicado: (2017)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies
por: Sganga, Gabriele, et al.
Publicado: (2019)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
por: Chan, Phylinda L.S., et al.
Publicado: (2021)

Anidulafungin for candidemia/invasive candidiasis in non-neutropenic ICU patients
por: Ruhnke, M, et al.
Publicado: (2011)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
por: Ruhnke, M, et al.
Publicado: (2012)

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
por: Auzinger, Georg, et al.
Publicado: (2015)

Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials
por: Kullberg, Bart Jan, et al.
Publicado: (2017)

Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study
por: van der Geest, Patrick J., et al.
Publicado: (2016)

Invasive Fungal Infections in Infants—Focus on Anidulafungin
por: Wilke, Michael H.
Publicado: (2013)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

Early Empirical Anidulafungin Reduces the Prevalence of Invasive Candidiasis in Critically Ill Patients: A Case-control Study
por: Hasan, Md Jahidul, et al.
Publicado: (2022)

Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil
por: Vianna, Cid Manso de Mello, et al.
Publicado: (2023)

β-D-glucan Surveillance with Preemptive Anidulafungin for Invasive Candidiasis in Intensive Care Unit Patients: A Randomized Pilot Study
por: Hanson, Kimberly E., et al.
Publicado: (2012)

Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies
por: De Rosa, Francesco Giuseppe, et al.
Publicado: (2021)

Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
por: Vazquez, Jose, et al.
Publicado: (2014)

Anidulafungin in the treatment of invasive fungal infections
por: Sabol, Kathryn, et al.
Publicado: (2008)

Anidulafungin and its role in candida infections
por: Cappelletty, Diane M, et al.
Publicado: (2009)

Pharmacokinetics of anidulafungin during albumin dialysis
por: Aguilar, Gerardo, et al.
Publicado: (2014)

Does Weight Impact Anidulafungin Pharmacokinetics?
por: Lempers, Vincent J., et al.
Publicado: (2016)

Anidulafungin: Lack of efficacy: case report
Publicado: (2022)

Epidemiological cohort study of systemic antifungal therapy for suspected or confirmed invasive candidiasis in the ICU: the Amarcand2 study
por: Constantin, J, et al.
Publicado: (2015)

A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators
por: Cristinacce, Andrew, et al.
Publicado: (2019)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
por: Auzinger, G, et al.
Publicado: (2013)

Anidulafungin/voriconazole: Lack of efficacy: case report
Publicado: (2022)

Anidulafungin/antibacterials: Failure of response: case report
Publicado: (2022)

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older
por: Franzese, Richard C., et al.
Publicado: (2021)

Anidulafungin compared with fluconazole therapy in critically ill patients
por: Kett, DH, et al.
Publicado: (2010)

Anidulafungin dosing during CRRT: do not underestimate adsorption!
por: Honore, Patrick M, et al.
Publicado: (2014)

Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation
por: Aguilar, Gerardo, et al.
Publicado: (2016)

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex
por: Marx, Jana, et al.
Publicado: (2020)

Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients
por: Suh, Jin Woong, et al.
Publicado: (2020)

Population Pharmacokinetics of Fosdagrocorat (PF‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis
por: Weatherley, Barry, et al.
Publicado: (2017)

375. Tolerability of Anidulafungin for Candidemia in Patients With Hepatic or Renal Dysfunction
por: Kim, Ji Young, et al.
Publicado: (2018)

Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling
por: Jacqmin, Philippe, et al.
Publicado: (2010)

Investigating the Subcortical Route to the Amygdala Across Species and in Disordered Fear Responses
por: McFadyen, Jessica
Publicado: (2019)

Counting the costs: Comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa
por: Smit, Jennifer, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ebo6h42tt5rpr3t5grd0sgaqgm